1 results match your criteria: "Mayo Clinic Rochester MN 55905 USA mansfield.aaron@mayo.edu.[Affiliation]"
RSC Adv
March 2025
Precision Cancer Therapeutics, Center for Individualized Medicine, Mayo Clinic Rochester MN 55905 USA
Despite ongoing efforts to employ structure-based methods to discover targeted protein degraders (TPD), the prevailing strategy continues to be the synthesis of a focused set of heterobifunctional compounds and screening them for target protein degradation. Here we used a fluorescence based live cell imaging screen to identify degraders that target exon 14 skipped hepatocyte growth factor receptor (MET). MET is a known oncogenic driver.
View Article and Find Full Text PDF